Optimising the impact of COVID-19 vaccination on mortality and hospitalisations using an individual additive risk measuring approach based on a risk adjustment scheme.
Additive risk measuring
COVID-19
Immunization strategy
Risk adjustment scheme
Severe outcomes
Vaccination prioritisation
Journal
The European journal of health economics : HEPAC : health economics in prevention and care
ISSN: 1618-7601
Titre abrégé: Eur J Health Econ
Pays: Germany
ID NLM: 101134867
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
26
05
2021
accepted:
03
11
2021
pubmed:
21
11
2021
medline:
26
7
2022
entrez:
20
11
2021
Statut:
ppublish
Résumé
In this population-based cohort study, billing data from German statutory health insurance (BARMER, 10% of population) are used to develop a prioritisation model for COVID-19 vaccinations based on cumulative underlying conditions. Using a morbidity-based classification system, prevalence and risks for COVID-19-related hospitalisations, ventilations and deaths are estimated. Trisomies, behavioural and developmental disorders (relative risk: 2.09), dementia and organic psychoorganic syndromes (POS) (2.23) and (metastasised) malignant neoplasms (1.99) were identified as the most important conditions for escalations of COVID-19 infection. Moreover, optimal vaccination priority schedules for participants are established on the basis of individual cumulative escalation risk and are compared to the prioritisation scheme chosen by the German Government. We estimate how many people would have already received a vaccination prior to escalation. Vaccination schedules based on individual cumulative risk are shown to be 85% faster than random schedules in preventing deaths, and as much as 57% faster than the German approach, which was based primarily on age and specific diseases. In terms of hospitalisation avoidance, the individual cumulative risk approach was 51% and 28% faster. On this basis, it is concluded that using individual cumulative risk-based vaccination schedules, healthcare systems can be relieved and escalations more optimally avoided.
Identifiants
pubmed: 34799804
doi: 10.1007/s10198-021-01408-8
pii: 10.1007/s10198-021-01408-8
pmc: PMC8604204
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
969-978Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
European Commission: Press statement by Commissioner Kyriakides on vaccine deliveries and on the vaccine export transparency scheme (2021)
Williams, J., Degeling, C., McVernon, J., Dawson, A.: How should we conduct pandemic vaccination? Vaccine (2021). https://doi.org/10.1016/j.vaccine.2020.12.059
doi: 10.1016/j.vaccine.2020.12.059
pubmed: 34980508
pmcid: 8719644
Bubar, K.M., Reinholt, K., Kissler, S.M., Lipsitch, M., Cobey, S., Grad, Y.H., Larremore, D.B.: Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science (2021). https://doi.org/10.1126/science.abe6959
doi: 10.1126/science.abe6959
pubmed: 33479118
pmcid: 7963218
Vygen-Bonnet, S., Bogdan, C., Heininger, U., Littmann, M., Meyer, H., Schmid-Küpke, N., Terhardt, M., Überla, K., van der Sande, M., Wichmann, O., Wicker, S., Wiedermann, U., Wild, V., von Kries, R.: Beschluss der STIKO zur 2. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung. Robert Koch Institute. Robert-Koch-Institut. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/02_21.pdf?__blob=publicationFile (2021)
Libotte, G.B., Lobato, F.S., Platt, G.M., Silva Neto, A.J.: Determination of an optimal control strategy for vaccine administration in COVID-19 pandemic treatment. Comput. Methods Programs Biomed. (2020). https://doi.org/10.1016/j.cmpb.2020.105664
doi: 10.1016/j.cmpb.2020.105664
pubmed: 32736332
pmcid: 7368913
Grauer, J., Löwen, H., Liebchen, B.: Strategic spatiotemporal vaccine distribution increases the survival rate in an infectious disease like COVID-19. Sci. Rep. (2020). https://doi.org/10.1038/s41598-020-78447-3
doi: 10.1038/s41598-020-78447-3
pubmed: 33299029
pmcid: 7726577
Kohli, M., Maschio, M., Becker, D., Weinstein, M.C.: The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine (2021). https://doi.org/10.1016/j.vaccine.2020.12.078
doi: 10.1016/j.vaccine.2020.12.078
pubmed: 33483216
pmcid: 7832653
Ribas, A., Sengupta, R., Locke, T., Zaidi, S.K., Campbell, K.M., Carethers, J.M., Jaffee, E.M., Wherry, E.J., Soria, J.-C., D’Souza, G.: Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited. Cancer Discov. (2020). https://doi.org/10.1158/2159-8290.CD-20-1817
doi: 10.1158/2159-8290.CD-20-1817
pubmed: 33355178
pmcid: 8053003
Mellado, B., Wu, J., Kong, J.D., Bragazzi, N.L., Asgary, A., Kawonga, M., Choma, N., Hayasi, K., Lieberman, B., Mathaha, T., Mbada, M., Ruan, X., Stevenson, F., Orbinski, J.: Leveraging artificial intelligence and big data to optimize COVID-19 clinical public health and vaccination roll-out strategies in Africa. Int. J. Environ. Res. Public Health (2021). https://doi.org/10.3390/ijerph18157890
doi: 10.3390/ijerph18157890
pubmed: 34360183
pmcid: 8345600
Russo, A.G., Decarli, A., Valsecchi, M.G.: Strategy to identify priority groups for COVID-19 vaccination: A population based cohort study. Vaccine (2021). https://doi.org/10.1016/j.vaccine.2021.03.076
doi: 10.1016/j.vaccine.2021.03.076
pubmed: 34663505
pmcid: 8492749
European Centre for Disease Prevention and Control (ECDC): COVID-19 vaccination and prioritisation strategies in the EU/EEA, Stockholm (2020)
Bundesministerium für Gesundheit: Verordnung zum Anspruch auf Schutzimpfung gegen das Coronavirus SARS-CoV-2 (Coronavirus-Impfverordnung). ImpfVO (2020)
Vygen-Bonnet, S., Bogdan, C., Heininger, U., Littmann, M., Meyer, H., Schmid-Küpke, N., Terhardt, M., Überla, K., van der Sande, M., Wichmann, O., Wicker, S., Wiedermann, U., Wild, V., von Kries, R.: Beschluss der STIKO für die Empfehlung der COVID-19-Impfung und die dazugehörige wissenschaftliche Begründung. STIKO-Empfehlung zur COVID-19-Impfung. Robert-Koch-Institut. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/02_21.pdf?__blob=publicationFile (2021)
Ellis, R.P., Martins, B., Rose, S.: Risk Adjustment for Health Plan Payment. In: Risk Adjustment, Risk Sharing and Premium Regulation in Health Insurance Markets, pp. 55–104. Elsevier (2018)
Dixon, J., Smith, P., Gravelle, H., Martin, S., Bardsley, M., Rice, N., Georghiou, T., Dusheiko, M., Billings, J., Lorenzo, M.D., Sanderson, C.: A person based formula for allocating commissioning funds to general practices in England: development of a statistical model. BMJ (Clin. Res. Ed.) (2011). https://doi.org/10.1136/bmj.d6608
doi: 10.1136/bmj.d6608
Cameron, A.C., Trivedi, P.K.: Microeconometrics. Methods and applications, 7th edn. Cambridge Univ. Press, Cambridge (2008)
Nagelkerke, N.J.D.: A note on a general definition of the coefficient of determination. Biometrika (1991). https://doi.org/10.1093/biomet/78.3.691
doi: 10.1093/biomet/78.3.691
de Hert, M., Mazereel, V., Detraux, J., van Assche, K.: Prioritizing COVID-19 vaccination for people with severe mental illness. World Psychiatry (2021). https://doi.org/10.1002/wps.20826
doi: 10.1002/wps.20826
pubmed: 33432763
pmcid: 7801854
Li, L., Li, F., Fortunati, F., Krystal, J.H.: Association of a prior psychiatric diagnosis with mortality among hospitalized patients with coronavirus disease 2019 (COVID-19) infection. JAMA Netw. Open (2020). https://doi.org/10.1001/jamanetworkopen.2020.23282
doi: 10.1001/jamanetworkopen.2020.23282
pubmed: 33355672
pmcid: 7758804
Wang, Q., Xu, R., Volkow, N.D.: Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry (2021). https://doi.org/10.1002/wps.20806
doi: 10.1002/wps.20806
pubmed: 34612005
pmcid: 8661963
Clift, A.K., Coupland, C.A.C., Keogh, R.H., Diaz-Ordaz, K., Williamson, E., Harrison, E.M., Hayward, A., Hemingway, H., Horby, P., Mehta, N., Benger, J., Khunti, K., Spiegelhalter, D., Sheikh, A., Valabhji, J., Lyons, R.A., Robson, J., Semple, M.G., Kee, F., Johnson, P., Jebb, S., Williams, T., Hippisley-Cox, J.: Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ (Clin. Res. Ed.) (2020). https://doi.org/10.1136/bmj.m3731
doi: 10.1136/bmj.m3731
McKeigue, P.M., Weir, A., Bishop, J., McGurnaghan, S.J., Kennedy, S., McAllister, D., Robertson, C., Wood, R., Lone, N., Murray, J., Caparrotta, T.M., Smith-Palmer, A., Goldberg, D., McMenamin, J., Ramsay, C., Hutchinson, S., Colhoun, H.M.: Rapid epidemiological analysis of comorbidities and treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. PLoS Med. (2020). https://doi.org/10.1371/journal.pmed.1003374
doi: 10.1371/journal.pmed.1003374
pubmed: 33079969
pmcid: 7575101